Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689236 | 0.93 | HPGD (0.49) | USP2SMN1; SMN2ESR2NR1H2HPGD | |
| SCHEMBL1063509 | 0.89 | ESR2 (0.52) | USP2SMN1; SMN2ESR2NR1H2HPGD | |
| Fluorobenzene SCHEMBL28128658 | 0.85 | MEN1 (0.52) | ESR2NR1H2GPR119MEN1KMT2A | |
| Chlorobenzene SCHEMBL28128624 | 0.85 | MEN1 (0.53) | USP2ESR2NR1H2HPGDGPR119 | |
| SCHEMBL8436771 | 0.85 | USP2 (0.55) | USP2SMN1; SMN2ESR2NR1H2HPGD | |
| SCHEMBL6615022 | 0.84 | HPGD (0.48) | USP2SMN1; SMN2HPGDGPR119RECQL | |
| SCHEMBL34461160 | 0.83 | GPR119 (0.58) | HPGDGPR119RECQLALDH1A1PTPN2 | |
| Ethylene SCHEMBL3832936 | 0.83 | USP2 (0.53) | USP2SMN1; SMN2ESR2NR1H2HPGD | |
| SCHEMBL24818255 | 0.82 | USP2 (0.56) | USP2SMN1; SMN2ESR2NR1H2HPGD | |
| SCHEMBL1813321 | 0.82 | USP2 (0.56) | USP2SMN1; SMN2ESR2NR1H2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1061 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290338-A | Building block 6-azaspiro [2.5] octane synthesized by Sovilnesib as anticancer medicine for clinical research and its synthesizing process | 上海苏博医药科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-115960411-A | Wire irradiation material and preparation method thereof | 江苏火凤凰线缆系统技术股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115754076-A | Gas chromatography for measuring related substances in 4-methylene piperidine hydrochloride | 江苏恒盛药业有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-106674112-A | Synthetic methods of 7-azaspiro[3,5]-nonane-2-ol and hydrochloride compound thereof | 苏州汉德创宏生化科技有限公司 | 2017-05-17 | — | — | CN | claimed |
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260116884-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-6140333-A | FOR TREATMENT AND/OR PROPHYLAXIS OF DISEASES INCLUDE SUCH RESPIRATORY DISEASES AS CHRONIC OBSTRUCTIVE PULMONARY DISEASES, CHRONIC BRONCHITIS, ASTHMA, CHRONIC RESPIRATORY OBSTRUCTION, PULMONARY FIBROSIS, PULMONARY EMPHYSEMA | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-10-31 | — | — | US | disclosed |
| US-6066636-A | ALZHEIMER'S DISEASE | SCHERING CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-2000000488-A1 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | USP2 1713/4885SMN1; SMN2 1897/4885ESR2 743/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | USP2 3172/4885SMN1; SMN2 1064/4885ESR2 884/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | USP2 100/4885SMN1; SMN2 1087/4885ESR2 3660/4885 |
| US-20260116884-A1 | PROTAC CHIMERIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CXCR1, TXK, CXCR4 | USP2 4142/4885SMN1; SMN2 4103/4885ESR2 1609/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | USP2 255/4885SMN1; SMN2 3271/4885ESR2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.